News

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid  Approval based on pivotal results showing improvements in sustained disease remission and ...
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...
Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...
A new study has found that people have such unique breathing patterns that researchers were able to identify subjects with ...
Using a newly devised, three-dimensional model to study the regeneration of nerve tissue in the nose, researchers at School ...